Intensity Therapeutics Azioni (NASDAQ: INTS)

Ultime notizie per Intensity Therapeutics (NASDAQ:INTS) Azioni

INTENSITY THERAPEUTICS INC

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Citigroup analyst Stephen Trent maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Neutral and raises the price target from $4.25 to $5.

News

Price Target

Analyst Ratings

JBLU

Citigroup Maintains Neutral on JetBlue Airways, Raises Price Target to $5

Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 55.77 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $479.80 thousand which beat the analyst consensus estimate of $100.00 thousand by 379.80 percent. This is a 524.46 percent increase over sales of $76.83 thousand the same period last year.

Earnings

Earnings Beats

Earnings Misses

CTNT

Cheetah Net Supply Chain Q1 EPS $(0.23) Misses $(0.21) Estimate, Sales $479.80K Beat $100.00K Estimate

Diamondback Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NYSE">FANG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/05/g45206097/diamondback-energy-inc-announces-first-quarter-2025-financial-and-operating-results">from the report. </a>
The Details: Diamondback Energy reported adjusted earnings of $4.54 per share, which beat the analyst consensus estimate of $4.13. Quarterly revenue clocked in at $4.05 billion, beating the $3.73 billion consensus estimate.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
For the first quarter, Diamondback Energy reported: 
<ul>
<li>Average oil production of 475.9 MBO/d (850.7 MBOE/d).</li>
<li>Net cash provided by operating activities of $2.4 billion; Operating Cash Flow Before Working Capital Changes of $2.5 billion.</li>
<li>Cash capital expenditures of $942 million.</li>
<li>Adjusted Free Cash Flow of $1.6 billion</li>
<li>Declared Q1 2025 base cash dividend of $1.00 per share payable on May&nbsp;22, 2025, implying a 2.9% annualized yield based on May&nbsp;2, 2025 closing share price of $136.81. </li>
</ul>
The company will host a conference call to discuss the results on Tuesday at 9 a.m. ET. 
Outlook: Diamondback Energy sees full-year 2025 oil production of 480 to 495 MBO/d (857-900 MBOE/d) and cash capital expenditures guidance of $3.4 billion to $3.8 billion.
FANG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Diamondback Energy stock was down 0.054% after-hours at $133.01 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Commodities

After-Hours Center

Movers

FANG

Diamondback Energy Reports Better-Than-Expected Q1: Details

Bain Capital Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCSF#NYSE">BCSF</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.47 by 6.38 percent. This is a 5.66 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $66.84 million which missed the analyst consensus estimate of $71.00 million by 5.86 percent. This is a 10.28 percent decrease over sales of $74.50 million the same period last year.

BCSF

Bain Capital Specialty Q1 EPS $0.50 Beats $0.47 Estimate, Sales $66.84M Miss $71.00M Estimate

FDA lifts clinical hold enabling resumption of clinical trials
FDA has granted a Type A Meeting to discuss path forward for BLA
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54249346&amp;newsitemid=20250505744665&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=1c32768a01374adbfe2795637b823f9c">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara's active Investigational New Drug (IND) applications for the EBVALLO&#x2122; (tabelecleucel) program.

Biotech

General

ATRA

Atara Biotherapeutics Provides Regulatory Updates On EBVALLO; FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials; FDA Has Granted A Type A Meeting To Discuss Path Forward For BLA

Stock Split

RNAZ

TransCode Therapeutics Approved An Effective Time At 12:01 a.m. Eastern Standard Time May 15, 2025, For Its 1-for-28 Reverse Stock Split

Citigroup analyst Kyle Menges maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Buy and raises the price target from $12 to $14.

Citigroup Maintains Buy on CNH Industrial, Raises Price Target to $14

Citigroup analyst Kyle Menges maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and raises the price target from $90 to $110.

AGCO

Citigroup Maintains Buy on AGCO, Raises Price Target to $110

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Neutral and lowers the price target from $10 to $9.5.

ARVN

Citigroup Maintains Neutral on Arvinas, Lowers Price Target to $9.5

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2025 GAAP EPS guidance from $6.75-$7.25 to $7.15-$7.65 vs $6.97 analyst estimate..

Guidance

STRL

Sterling Infrastructure Raises FY2025 GAAP EPS Guidance From $6.75-$7.25 To $7.15-$7.65 vs $6.97 Est

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2025 Adj EPS guidance from $7.90-$8.40 to $8.40-$8.90 vs $7.27 analyst estimate. Raises FY2025 sales outlook from $2.00 billion-$2.15 billion to $2.05 billion-$2.15 billion vs $2.02 billion estimate.

CORRECTION: Sterling Infrastructure Raises FY2025 Adj EPS Guidance from $7.90-$8.40 to $8.40-$8.90 vs $7.27 Est; Raises FY2025 Sales Guidance from $2.00B-$2.15B to $2.05B-$2.15B vs $2.02B Est

Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.39%. Currently, Home Depot has a market capitalization of $359.57 billion. 
Buying $1000 In HD: If an investor had bought $1000 of HD stock 10 years ago, it would be worth $3,232.62 today based on a price of $361.73 for HD at the time of writing.
<h3>Home Depot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746479725_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Home Depot Stock In The Last 10 Years

Timbercreek Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TF#TSX">TF</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.16 by 18.75 percent. This is a 11.76 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $28.57 million which beat the analyst consensus estimate of $27.07 million by 5.55 percent. This is a 16.20 percent increase over sales of $24.59 million the same period last year.

TSX:TF

Timbercreek Financial Q1 Adj. EPS $0.19 Beats $0.16 Estimate, Sales $28.57M Beat $27.07M Estimate

Today the company's board of directors appointed William C. Whitaker, vice president, finance, and director, investor relations, to serve as the company's interim chief financial officer until the board concludes its review process. &nbsp;

Management

Ashland Appoints William C. Whitaker, Vice President, Finance, And Director, Investor Relations, To Serve As The Company's Interim CFO Until The Board Concludes Its Review Process

&nbsp;(All dollar amounts are expressed in Canadian dollars, unless otherwise noted.)
TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Kinross Gold Corporation ("Kinross" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/K#TSX">K</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) announced today that it has acquired an aggregate of 7,574,237 units (each, a "Unit") of Eminent Gold Corp. ("Eminent") at a price of $0.40 per Unit and an aggregate purchase price of $3,029,694.80 (the "Acquisition"), pursuant to the closing of a private placement by Eminent of 10,711,900 Units. Each Unit consisted of one common share in the capital of Eminent (each, a "Share") and one-half of one Share purchase warrant (each whole warrant being a "Warrant"). Each Warrant shall entitle the holder thereof to acquire one Share at an exercise price of $0.70 per Share for a period of 24 months from their issuance.
Prior to the Acquisition, Kinross did not own or have control over any securities of Eminent. As a result of the Acquisition, Kinross acquired an aggregate of 7,574,237 Shares and 3,787,118 Warrants, representing approximately 9.9% of the issued and outstanding Shares on a non-diluted basis and 14.15% of the issued and outstanding Shares on a partially diluted basis.

TSX:K

Kinross Gold Acquires 7.57M Units Of Eminent Gold For C$3.03M In Private Placement Deal, Gaining Shares And Warrants With 2-Year Option To Purchase Additional Stock At C$0.70 Per Share

Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) released its third-quarter results after Monday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/05/n45206776/clorox-reports-q3-fiscal-year-2025-results-updates-outlook"> from the report.&nbsp;</a>
The Details:&nbsp;Clorox reported quarterly earnings of $1.45 per share, which missed the analyst consensus estimate of $1.57. Quarterly revenue came in at $1.67 billion, which missed the analyst consensus estimate of $1.73 billion and is down from revenue of $1.81 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
The company reported gross margin&nbsp;increased 240 basis points to 44.6% from 42.2% in the year-ago quarter, primarily driven by cost savings and the benefits from the divestitures of the VMS and&nbsp;Argentina&nbsp;businesses.
&#8220;In the third quarter, heightened macroeconomic uncertainties drove changes in shopping behaviors, resulting in temporary category slowdowns and lower sales. We expect these slowdowns to persist in the fourth quarter, as reflected in our updated outlook,&#8221; said CEO&nbsp;Linda Rendle.&nbsp;
Outlook:&nbsp;Clorox affirmed its fiscal 2025 adjusted EPS guidance of&nbsp;$6.95 to $7.35&nbsp;per share, versus the $7.12&nbsp;analyst estimate. The company narrowed its fiscal year revenue outlook from a range of&nbsp;$7.02 billion to $7.24 billion&nbsp;to&nbsp;a range of $7.02 billion to $7.09 billion, below the $7.1 billion&nbsp;estimate.
CLX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Clorox stock was down 4.06% after-hours at $132.77 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Clorox Stock Drops After Worse-Than-Expected Q3 Results: 'Heightened Macroeconomic Uncertainties' Lowered Sales, CEO says

BTB REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTB#TSX">BTB</a>) reported quarterly earnings of $0.10 per share. This is a 15.73 percent increase over earnings of $0.09 per share from the same period last year. The company reported $34.41 million in sales this quarter. This is a 5.44 percent increase over sales of $32.64 million the same period last year.

TSX:BTB

BTB REIT Q1 FFO $0.10 Up From $0.09 YoY, Sales $34.41M Up From $32.64M YoY

Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) lowers FY2025 FFO guidance from $6.82-$7.06 to $6.43-$6.63 vs $6.42 analyst estimate..

Sun Communities Lowers FY2025 FFO Guidance From $6.82-$7.06 To $6.43-$6.63 Vs $6.42 Est

Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) is looking for Q2 FFO of $1.62-$1.70 vs $1.74 analyst estimate..

Sun Communities Sees Q2 FFO $1.62-$1.70 vs $1.74 Est

UBS analyst Kevin Caliendo maintains Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) with a Neutral and lowers the price target from $21 to $18.

NVST

UBS Maintains Neutral on Envista Holdings, Lowers Price Target to $18

Press Releases

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Offerings

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

INTS

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

iBio

Immuron Limited - American Depositary Shares

Immuron

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Intensity Therapeutics

Notizie

Ultime notizie per Intensity Therapeutics (NASDAQ:INTS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO